PGNY vs GDRX

For growth investors, Progyny, Inc.

(PGNY) is the stronger pick with 10. 4% revenue growth year-over-year, versus 0. 6% for GoodRx Holdings, Inc. (GDRX). Progyny, Inc. (PGNY) offers the better valuation at 29. 5x trailing P/E (16. 4x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Progyny, Inc.

(PGNY) is the cheapest at 29. 5x versus GoodRx Holdings, Inc. at 33. 3x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Progyny, Inc.

(PGNY) delivered a total return of -62. 9%, compared to -91. 8% for GoodRx Holdings, Inc. (GDRX). Over 10 years, the gap is even starker: PGNY returned +20. 2% versus GDRX's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Progyny, Inc.

(PGNY) is the lower-risk stock at 0. 71β versus GoodRx Holdings, Inc. 's 1. 58β — meaning GDRX is approximately 123% more volatile than PGNY relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 10% for GoodRx Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Progyny, Inc.

(PGNY) is pulling ahead at 10. 4% versus 0. 6% for GoodRx Holdings, Inc. (GDRX). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to 14. 0% for Progyny, Inc.. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Progyny, Inc.

(PGNY) is the more profitable company, earning 4. 5% net margin versus 3. 8% for GoodRx Holdings, Inc. — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus 6. 6% for PGNY. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 0x forward P/E versus 16. 4x for Progyny, Inc. — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Progyny, Inc.

(PGNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). GoodRx Holdings, Inc. (GDRX) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PGNY: +20. 2%, GDRX: -94. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.